Brain Tumor Clinical Trial
Official title:
Assessing the Efficacy of Immediate Release Methylphenidate, Sustained Release Methylphenidate and Modafinil for Patients With Brain Tumors
Primary Objective:
- To assess the efficacy of immediate release methylphenidate, sustained release
methylphenidate, and the novel vigilance enhancing drug modafinil for the improvement of
cognitive functioning in patients with brain tumors.
All three drugs used in this clinical research study are widely used stimulants to help
cancer patients who have fatigue and problems with concentration.
Before treatment starts, you will have a physical exam, including measurement of blood
pressure, and neuropsychological and symptom evaluations. The neuropsychological evaluation
is made up of tests of attention, memory, speech, and other brain functions, and takes about
30 minutes to complete. The other test evaluates symptoms you may be experiencing, such as
fatigue or depression, and takes about 10 minutes to complete.
You will be randomly assigned (as in the toss of a coin) to one of three treatment groups.
Participants in the first group will receive Immediate Release (IR) methylphenidate.
Participants in the second group will receive Sustained Release (SR) methylphenidate.
Participants in the third group will receive modafinil. There is an equal chance of being
assigned to any of the groups. After you are randomized, you will contact the M. D. Anderson
pharmacy to receive your assigned medication. You will receive a total of 5 weeks worth of
medication. The extra week of medication is to allow for buffer should there be any conflict
in rescheduling the follow-up evaluation.
IR methylphenidate is a pill taken twice a day. Both SR methylphenidate and modafinil are
pills taken once a day. The amount of the medicine is the same for all three groups. You will
take the medication every day for a total of 4 weeks.
You will be asked to complete a study calendar, which will be provided by the research staff.
In the study calendar, you will be asked to initial after you take the study drug each day,
and to record any side effects you may experience. You will be required to return the
completed study calendar at the final evaluation visit, along with the empty bottles and any
of the study drugs that may be left over.
You will remain on treatment for 4 weeks and return for a final evaluation. A follow-up
neuropsychological evaluation and evaluation of symptoms will be performed. At the end of the
study treatment period, you will be allowed to remain on active treatment if you wish to. You
can discuss with your doctor whether to continue on the same medication or to try another
one.
This is an investigational study. All of the study drugs are FDA approved and currently are
used to help brain tumor patients. A total of 75 patients will take part in this study. All
will be enrolled at M. D. Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03286335 -
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
|
N/A | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
| Recruiting |
NCT03276676 -
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
|
Phase 2 | |
| Completed |
NCT02851355 -
Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
|
||
| Completed |
NCT02558569 -
The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
|
Phase 4 | |
| Completed |
NCT02409121 -
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
|
N/A | |
| Completed |
NCT02713087 -
Vasopressor Effects in Anesthetized Patients
|
Phase 4 | |
| Terminated |
NCT02674945 -
Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
|
||
| Withdrawn |
NCT02165995 -
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
|
N/A | |
| Withdrawn |
NCT01202539 -
Real-time Assessment of Frameless Intrafraction Motion
|
||
| Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
| Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00760409 -
Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI
|
N/A | |
| Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 |